TipRanks
Advertisement
Advertisement

PCVX Stock Latest News

Vaxcyte Bolsters Capital Structure with New Offerings
Company AnnouncementsVaxcyte Bolsters Capital Structure with New Offerings
12d ago
8K
PCVX
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
PremiumMarket News
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
14d ago
AZN
MRK
Vaxcyte 7.412M share Spot Secondary priced at $64.00
PremiumThe Fly
Vaxcyte 7.412M share Spot Secondary priced at $64.00
14d ago
PCVX
Vaxcyte falls -11.3%
PremiumThe Fly
Vaxcyte falls -11.3%
15d ago
PCVX
Vaxcyte price target raised to $146 from $130 at BofA
PremiumThe Fly
Vaxcyte price target raised to $146 from $130 at BofA
15d ago
PCVX
Vaxcyte files to sell $500M of common stock, $500M of convertible senior notes
PremiumThe FlyVaxcyte files to sell $500M of common stock, $500M of convertible senior notes
16d ago
PCVX
Vaxcyte price target raised to $122 from $110 at Needham
Premium
The Fly
Vaxcyte price target raised to $122 from $110 at Needham
16d ago
PCVX
Midday Fly By: Schneider to buy PTC, C.H. Robinson to acquire RXO
Premium
The Fly
Midday Fly By: Schneider to buy PTC, C.H. Robinson to acquire RXO
16d ago
AN
TC
Vaxcyte rises 33.7%
PremiumThe Fly
Vaxcyte rises 33.7%
16d ago
PCVX
Vaxcyte rises 46.4%
PremiumThe Fly
Vaxcyte rises 46.4%
16d ago
PCVX
Vaxcyte data hit ‘blue-sky’ case, says Jefferies
PremiumThe Fly
Vaxcyte data hit ‘blue-sky’ case, says Jefferies
16d ago
PCVX
Vaxcyte can trade in $90-$100 range on data, says Mizuho
PremiumThe Fly
Vaxcyte can trade in $90-$100 range on data, says Mizuho
16d ago
PCVX
Vaxcyte Announces Positive Phase 3 Results for VAX-31
PremiumCompany AnnouncementsVaxcyte Announces Positive Phase 3 Results for VAX-31
16d ago
8K
PCVX
Vaxcyte price target raised to $125 from $116 at Guggenheim
Premium
The Fly
Vaxcyte price target raised to $125 from $116 at Guggenheim
16d ago
PCVX
Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31
Premium
The Fly
Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31
16d ago
PCVX
Mizuho biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Mizuho biotech analysts hold an analyst/industry conference call
20d ago
BBIO
BIIB
Vaxcyte price target lowered to $130 from $133 at BofA
PremiumThe Fly
Vaxcyte price target lowered to $130 from $133 at BofA
23d ago
PCVX
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline
PremiumCompany Announcements
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline
2M ago
8K
PCVX
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
PremiumThe Fly
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
2M ago
PFE
PCVX
Vaxcyte narrows previously communicated VAX-31 guidance
PremiumThe FlyVaxcyte narrows previously communicated VAX-31 guidance
2M ago
PCVX
Analyst Reiterates Buy Rating and Maintains $110 Price Target on Robust Vaccine Pipeline and Upcoming Clinical Catalysts
Premium
Ratings
Analyst Reiterates Buy Rating and Maintains $110 Price Target on Robust Vaccine Pipeline and Upcoming Clinical Catalysts
3M ago
PCVX
Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)
Premium
The Fly
Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)
3M ago
PCVX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >